DIAGNOS Provides Additional Information on Amendment to Convertible Debentures

Provided By GlobeNewswire

Last update: Apr 14, 2025

BROSSARD, Quebec, April 14, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence (AI), wishes to provide additional information to the February 28, 2025 announcement on amendment to convertible debentures.